Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Seres Therapeutics

Seres Therapeutics

Seres Therapeutics is a microbiome therapeutics company that was founded in 2010 and headquartered in Cambridge, Massachusetts.

Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies.

Funding
Series A

On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.

Series B

On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture.

Series C

On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering.

Series D

On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science.

Timeline

October 2017
Seres Therapeutics raises a $2,500,000 grant from Carb-X.
January 2015
Seres Therapeutics raises a $65,000,000 series D round from Nestlé Health Science.
December 2014
Seres Therapeutics raises a $48,000,000 series C round from Flagship Pioneering.
May 2014
Seres Therapeutics raises a $10,000,000 series B round from Alexandria Venture Investments, Enso Ventures, Flagship Pioneering and Mayo Clinic.
November 2013
Seres Therapeutics raises a $10,500,000 series B round from Enso Ventures and Flagship Pioneering.
2010
Seres Therapeutics was founded by David Berry and Noubar Afeyan.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Ben Adams
July 22, 2021
FierceBiotech
There's been precious little good news for Seres Therapeutics of late, and the woe continues today as it records another trial failure. Shares in the microbiome biotech fell more than 52% to $9.90 in early, premarket trading Thursday morning, from a prior close of $20.73.
Brandon May
July 1, 2021
BioSpace
Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres's investigational oral microbiome treatment for recurrent Clostridioides difficile infections.
Amirah Al Idrus
July 1, 2021
FierceBiotech
After a rough couple of years, things are looking up for Seres Therapeutics. The microbiome company's partner Nestlé Health Sciences is handing over $175 million upfront to help market its lead microbiome treatment in North America.
Mark Zipkin
June 10, 2021
BioSpace
With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.
May 21, 2021
BioSpace
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021 - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.